Overview

* Alpha Teknova ( TKNO ) Q2 revenue rises 7% yr/yr, beating analyst expectations

* Company achieves four consecutive quarters of revenue growth

* Teknova reaffirms 2025 revenue guidance of $39-42 mln

Outlook

* Alpha Teknova ( TKNO ) reaffirms 2025 revenue guidance of $39-42 mln

* Company anticipates 2025 free cash outflow under $12 mln

* Alpha Teknova ( TKNO ) expects sustainable growth despite macroeconomic uncertainties

Result Drivers

* MANUFACTURING EFFICIENCY - Gross margin improved to 38.7% from 29.2% due to manufacturing efficiency gains and higher revenue

* CLINICAL SOLUTIONS GROWTH - Revenue in Clinical Solutions segment increased by 32%, contributing to overall revenue growth

* COST MANAGEMENT - Operating expenses decreased due to reduced spending on insurance and facility costs

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $10.29 $9.91

Revenue mln mln (5

Analysts

)

Q2 EPS -$0.07

Q2 Net -$3.57

Income mln

Q2 Free -$2.30

Cash mln

Flow

Q2 Gross $3.98

Profit mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for Alpha Teknova Inc ( TKNO ) is $11.00, about 60.5% above its August 6 closing price of $4.35

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)